PV QA 4 - Poster Viewing Q&A 4
TU_16_3475 - A Comprehensive Analysis of the Therapeutic Efficacy, Toxicity and Prognostic Factors in FIGO IIIB Cervical Cancer Patients
Tuesday, October 23
2:45 PM - 4:15 PM
Location: Innovation Hub, Exhibit Hall 3
A Comprehensive Analysis of the Therapeutic Efficacy, Toxicity and Prognostic Factors in FIGO IIIB Cervical Cancer Patients
Q. Meng1, K. Hu2, and F. Zhang3; 1Peking Union Medical College Hospital,Dept. of radiation oncology, Beijing, China, 2PUMCH, peking, China, 3Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China
Purpose/Objective(s): Cervical cancer is one of the most prevalent cancers in women worldwide despite dramatic advances in the prevention of this cancer has been achieved in last few decades. We aim to uncover the prognostic factors for FIGO IIIB cervical cancer. Moreover, we want to investigate whether high dose irradiation can improve therapeutic efficacy and whether prophylactic extended field irradiation is beneficial for patients without para-aortic LN metastasis.
Materials/Methods: We performed a retrospective analysis in 223 FIGO IIIB cervical cancer patients with intact clinical documents and completed follow-ups from 2000 to 2014. We first analyzed 5 years OS, DFS, LCR and DMFS. To fully understand various prognostic factors contributing to IIIB cervical cancer progression, patients were divided not only based on their clinical tumor-related features, but also according to the treatment they received. Finally, we performed both univariate and multivariate analysis to uncover prognostic factors that correlated with OS, DFS, LCR and DMFS of IIIB cervical cancer patients.
Results: The five years OS, DFS, LCR, DMFS for our patients were 61.1%, 55.2%, 83.6% and 66.4% respectively. Multivariate analysis revealed that pelvic and para-aortic LN metastasis, EQD2(point A) and concurrent chemotherapy cycles were independent prognostic factors for OS; pelvic and para-aortic LN metastasis, EQD2 (point A), HGB level and concurrent chemotherapy cycles were independent prognostic factors for DFS; para-aortic LN metastasis and EQD2(point A) were independent prognostic factors for LCR; concurrent chemotherapy was the only prognostic factor for DMFS. Importantly, we observed that high dose of EQD2 (point A) could significantly improve OS, DFS and LCR for FIGO IIIB cervical cancer patients, furthermore, for those patients without para-aortic LN metastasis, prophylactic extended field irradiation had a clear tendency to improve OS and DMFS as well as a significant survival advantage for DFS.
Conclusion: We highly recommend that FIGO IIIB cervical cancer patients should receive personalized higher EQD2 (≥98Gy) radiotherapy when possible. Moreover, we also propose that prophylactic extended field irradiation is an important prevention strategy for those patients without para-aortic LN metastasis.
Author Disclosure: Q. Meng: None. K. Hu: None. F. Zhang: None.